{"id":2783,"date":"2026-10-26T20:45:50","date_gmt":"2026-10-26T20:45:50","guid":{"rendered":"https:\/\/hscodematch.com\/news\/eu-drops-drug-ingredient-certificate-for-singapore-shipments-from-15\/"},"modified":"2026-10-26T20:45:52","modified_gmt":"2026-10-26T20:45:52","slug":"eu-drops-drug-ingredient-certificate-for-singapore-shipments-from-15","status":"publish","type":"post","link":"https:\/\/hscodematch.com\/news\/eu-drops-drug-ingredient-certificate-for-singapore-shipments-from-15\/","title":{"rendered":"EU Drops Drug Ingredient Certificate for Singapore Shipments from 15 November 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph hsn-lede\">European Union drops the written confirmation for medicine ingredients made in Singapore, starting Nov. 15, 2026.<\/p>\n<p class=\"wp-block-paragraph\">The European Commission has added Singapore to its list of countries whose medicine-ingredient controls match European Union (EU) rules, effective Nov. 15, 2026.<\/p>\n<p class=\"wp-block-paragraph\">The change is set out in Commission Implementing Decision (EU) 2026\/2347 of Oct. 23, 2026, published in the Official Journal of the European Union on Oct. 26, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\" id=\"hsn-cite-1\">1<\/a><\/sup>. It replaces the list in an older decision from 2012, which names the non-EU countries that enjoy this status<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">In short, active ingredients for human medicines made in Singapore will no longer need a special certificate from Singapore&#8217;s authorities for each shipment to the EU. A European buyer can import them on the same paperwork terms as ingredients from the United States, Japan or Switzerland.<\/p>\n<h2 class=\"wp-block-heading\">What is changing for Singapore drug ingredients?<\/h2>\n<p class=\"wp-block-paragraph\">The goods concerned are <strong>active pharmaceutical ingredients<\/strong>, the substances in a medicine that treat the illness. EU law calls them &quot;active substances&quot;<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Since 2013, these ingredients may enter the EU only with a <strong>written confirmation<\/strong> from the authority of the exporting country<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\" id=\"hsn-cite-2\">2<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3\" data-at=\"what-is-changing-for-singapore-drug-ingredients\">\n  <div class=\"hsn-fig__table\">\n    <h4>Singapore ingredient shipments, before and after<\/h4>\n    <div class=\"pcrstb-wrap\"><table>\n      <thead>\n        <tr><th>Question<\/th><th>Before Nov. 15, 2026<\/th><th>From Nov. 15, 2026<\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><th>Singapore on EU list?<\/th><td>No<\/td><td>Yes<\/td><\/tr>\n        <tr><th>Written confirmation needed?<\/th><td>Yes, with each shipment<\/td><td>No<\/td><\/tr>\n        <tr><th>Quality rules for making ingredients<\/th><td>At least equal to EU rules<\/td><td>At least equal to EU rules<\/td><\/tr>\n      <\/tbody>\n    <\/table><\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">The written confirmation is an official letter from that authority. It states that the factory follows good manufacturing practice, the quality rules for making medicines, at a level at least equal to the EU&#8217;s<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. It also confirms that the factory faces regular, strict controls, including repeated and unannounced inspections<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The European Commission waives this letter for a short list of countries<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\" id=\"hsn-cite-3\">3<\/a><\/sup>. Ingredients made in a listed country do not need a written confirmation<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\" id=\"hsn-cite-4\">4<\/a><\/sup>. With the new decision, Singapore joins that list<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Which countries are on the EU list now?<\/h2>\n<p class=\"wp-block-paragraph\">The new decision replaces the whole annex, or attached list, of Implementing Decision 2012\/715\/EU<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. After the change, the list has <strong>10 countries and territories<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>:<\/p>\n<ul>\n<li>Australia<\/li>\n<li>Brazil<\/li>\n<li>Canada<\/li>\n<li>Israel<\/li>\n<li>Japan<\/li>\n<li>Singapore<\/li>\n<li>South Korea<\/li>\n<li>Switzerland<\/li>\n<li>Taiwan<\/li>\n<li>United States<\/li>\n<\/ul>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3\" data-at=\"which-countries-are-on-the-eu-list-now\">\n    <div class=\"hsn-fig__cols\">\n    <h4>Places on the EU equivalence list<\/h4>\n    <div class=\"hsn-fig__col\" data-series=\"1\">\n      <span class=\"hsn-fig__num\">1<\/span>\n      <span class=\"hsn-fig__coltrack\"><span class=\"hsn-fig__colfill\" data-v=\"10\"><\/span><\/span>\n      <span class=\"hsn-fig__lab\">2012 list<\/span>\n    <\/div>\n    <div class=\"hsn-fig__col\" data-series=\"1\">\n      <span class=\"hsn-fig__num\">10<\/span>\n      <span class=\"hsn-fig__coltrack\"><span class=\"hsn-fig__colfill\" data-v=\"100\"><\/span><\/span>\n      <span class=\"hsn-fig__lab\">After the 2026 decision<\/span>\n    <\/div>\n  <\/div><\/figure>\n<p class=\"wp-block-paragraph\">The list began in 2012 with Switzerland as its only entry<sup class=\"hsn-cite\"><a href=\"#hsn-ref-5\" id=\"hsn-cite-5\">5<\/a><\/sup>. The Commission&#8217;s public health department records when each other country was added<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. For example, the United States joined in June 2013, Canada in January 2023 and Taiwan in November 2023<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The list covers countries and territories, and it is not limited to countries the EU recognises<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. The decision adds two notes. One limits Israel&#8217;s entry to the State of Israel, without the territories under Israeli administration since June 1967<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The other says the Taiwan entry reflects no EU position on Taiwan&#8217;s legal status<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Why did the European Commission list Singapore?<\/h2>\n<p class=\"wp-block-paragraph\">EU medicines law lets a non-EU country ask to be assessed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The Commission then checks whether that country&#8217;s rules for exported active ingredients protect public health as well as EU rules do<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It also checks the country&#8217;s inspections and enforcement<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3\" data-at=\"why-did-the-european-commission-list-singapore\">\n  <div class=\"hsn-fig__axis\">\n    <h4>From request to listing<\/h4>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">11 Feb 2025<\/span>\n      <span class=\"hsn-fig__evlab\">Singapore asks to be listed<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">18-25 Mar 2026<\/span>\n      <span class=\"hsn-fig__evlab\">On-site review<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">26 Oct 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Decision published<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">15 Nov 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Decision takes effect<\/span>\n    <\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">Singapore asked to be listed in a <strong>letter dated Feb. 11, 2025<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The Commission reviewed Singapore&#8217;s documents. It also sent a team to review Singapore&#8217;s system on site <strong>from March 18 to 25, 2026<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">That on-site review included two observed inspections<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It also took account of answers and documents from the Health Sciences Authority (HSA), Singapore&#8217;s medicines regulator<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Based on this assessment, the Commission concluded that Singapore met the legal requirements<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Why did Singapore wait so long?<\/h2>\n<p class=\"wp-block-paragraph\">Singapore first asked to be listed on Sept. 17, 2012, according to the Commission&#8217;s application table<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. That first request did not lead to a listing<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The table gives the reason. Singapore&#8217;s law at the time had a non-mandatory certification scheme for good manufacturing practice<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. The Commission noted that contacts continued and that, in the meantime, Singapore issued written confirmations<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The 2025 request led to the full assessment and the new decision<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The Commission&#8217;s online table still shows the old 2012 status and has not yet been updated for the decision<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How does the written confirmation work today?<\/h2>\n<p class=\"wp-block-paragraph\">The Commission&#8217;s questions-and-answers guide on importing active ingredients explains the current rules<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. These rules are found in Articles 46b and 111b of Directive 2001\/83\/EC, the main EU law on human medicines<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">For a factory in a non-listed country, the process works in these steps<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>:<\/p>\n<ol>\n<li>The authority of the country where the ingredient is made issues a written confirmation for the factory.<\/li>\n<li>The confirmation covers that factory and the named ingredients made there, not a single batch.<\/li>\n<li>Each shipment to the EU carries the confirmation, or a copy if the original is still valid.<\/li>\n<li>The EU maker of the finished medicine checks that the confirmation came with the shipment.<\/li>\n<\/ol>\n<p class=\"wp-block-paragraph\">National authorities may also check the papers at import or during inspections, depending on each EU country&#8217;s law<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. The issuing authority sets how long a confirmation stays valid<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. The confirmation must come from the country where the ingredient is made, even if it is shipped through another country<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Once the decision applies, step 1 and step 3 fall away for ingredients made in Singapore. Singapore&#8217;s factories no longer need an HSA letter, and <strong>each shipment no longer needs one<\/strong> to enter the EU.<\/p>\n<h2 class=\"wp-block-heading\">Which goods are covered and which are not?<\/h2>\n<p class=\"wp-block-paragraph\">The rules apply only to active ingredients for medicines for <strong>human use<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. Ingredients for veterinary medicines are outside the written confirmation rules<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. Blood plasma is also outside, but processed plasma products with a medical action count as active ingredients<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3\" data-at=\"which-goods-are-covered-and-which-are-not\">\n  <div class=\"hsn-fig__table\">\n    <h4>What the written confirmation rules cover<\/h4>\n    <div class=\"pcrstb-wrap\"><table>\n      <thead>\n        <tr><th>Goods<\/th><th>Rule<\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><th>Active ingredients for human medicines<\/th><td>Covered<\/td><\/tr>\n        <tr><th>Ingredients for veterinary medicines<\/th><td>Not covered<\/td><\/tr>\n        <tr><th>Finished medicines<\/th><td>Separate import rules<\/td><\/tr>\n        <tr><th>Starting materials and intermediates<\/th><td>Not covered<\/td><\/tr>\n        <tr><th>Ingredients for EU medicines made only for export<\/th><td>Covered<\/td><\/tr>\n      <\/tbody>\n    <\/table><\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">The guide lists several other cases outside the rules<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>:<\/p>\n<ul>\n<li><strong>Finished medicines<\/strong>: these follow separate import rules, including an import licence and batch release by a qualified person.<\/li>\n<li><strong>Starting materials and intermediates<\/strong>: chemicals used to make an active ingredient do not count as the ingredient itself.<\/li>\n<li><strong>Ingredients already mixed<\/strong> with other substances but not yet a finished medicine.<\/li>\n<li><strong>Ingredients passing through<\/strong> the EU for export without being imported.<\/li>\n<li><strong>Ingredients for research trials<\/strong> of unauthorised medicines.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">A written confirmation is still needed when the finished medicine made in the EU is only for export<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. If an ingredient arrives without a confirmation, it cannot be used in a human medicine<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Who is affected by the Singapore listing?<\/h2>\n<p class=\"wp-block-paragraph\"><strong>Makers in Singapore<\/strong> that sell active ingredients to EU buyers gain the most. They will no longer need to request a written confirmation from the HSA for each factory and ingredient<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\"><strong>EU importers of active ingredients<\/strong> and EU medicine makers using Singapore ingredients also benefit. They will no longer need to check for a written confirmation on Singapore shipments<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. The listing confirms the Commission&#8217;s view that Singapore&#8217;s controls protect public health as well as EU controls do<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The rules on quality stay in place. Active ingredients must still be made under good manufacturing practice at least equal to EU standards<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. The EU standard for making active ingredients is ICH Q7, a guideline from the International Conference for Harmonisation<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The decision does not change paperwork for ingredients made elsewhere. The written confirmation must come from the country of manufacture<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. So an ingredient made in another non-listed country still needs that country&#8217;s confirmation, even if it is shipped through Singapore.<\/p>\n<h2 class=\"wp-block-heading\">What other checks still apply?<\/h2>\n<p class=\"wp-block-paragraph\">EU inspections continue whatever the paperwork. When an EU country finds a factory does not follow good manufacturing practice, it issues a statement of non-compliance<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. Such statements are stored in the EudraGMDP database, an EU database of factory inspections, and are public<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The guide also notes that the written confirmation is separate from mutual recognition agreements<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. These are deals in which the EU and another country accept each other&#8217;s factory inspections<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. A listing under the 2012 decision is a different status from such an agreement.<\/p>\n<p class=\"wp-block-paragraph\">In some cases, an EU country may waive the written confirmation for a non-listed factory it has inspected<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. This happens only exceptionally, when needed to keep medicines available, and for no longer than the factory&#8217;s quality certificate is valid<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">When does the Singapore change take effect?<\/h2>\n<p class=\"wp-block-paragraph\">The decision enters into force on the <strong>20th day after publication<\/strong> in the Official Journal<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Publication was on Oct. 26, 2026, so the decision takes effect on <strong>Nov. 15, 2026<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Until that date, shipments of active ingredients from Singapore still need the written confirmation. The Commission&#8217;s guide also covers shipments made under a confirmation that has since expired<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>. Such a shipment can still be imported if its papers prove it was made and released before the expiry date<sup class=\"hsn-cite\"><a href=\"#hsn-ref-4\">4<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Key points on Singapore drug ingredients<\/h2>\n<p class=\"wp-block-paragraph\">The table sums up the decision and its effect on shipments.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Question<\/th><th>Answer<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>What changed?<\/td><td>Singapore added to EU equivalence list<\/td><\/tr>\n<tr><td>Which measure?<\/td><td>Implementing Decision (EU) 2026\/2347<\/td><\/tr>\n<tr><td>Who issued it?<\/td><td>European Commission<\/td><\/tr>\n<tr><td>Which goods?<\/td><td>Active ingredients for human medicines<\/td><\/tr>\n<tr><td>What paperwork goes?<\/td><td>Written confirmation for Singapore-made ingredients<\/td><\/tr>\n<tr><td>Who is Singapore&#8217;s regulator?<\/td><td>Health Sciences Authority (HSA)<\/td><\/tr>\n<tr><td>When did Singapore ask?<\/td><td>Feb. 11, 2025<\/td><\/tr>\n<tr><td>When was the on-site review?<\/td><td>March 18 to 25, 2026<\/td><\/tr>\n<tr><td>How many places on the list?<\/td><td>10 countries and territories<\/td><\/tr>\n<tr><td>When published?<\/td><td>Oct. 26, 2026<\/td><\/tr>\n<tr><td>When does it apply?<\/td><td>Nov. 15, 2026<\/td><\/tr>\n<tr><td>What is not covered?<\/td><td>Veterinary ingredients and finished medicines<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">From Nov. 15, 2026, active ingredients made in Singapore can enter the EU without a written confirmation. They will join ingredients from the nine other listed countries and territories, while quality rules and EU inspections stay in place.<\/p>\n<h2 class=\"wp-block-heading hsn-refs-title\">Sources<\/h2>\n<ol class=\"hsn-refs\">\n<li id=\"hsn-ref-1\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-1\" aria-label=\"Back to reference 1 in the text\">\u21a9<\/a> <a href=\"https:\/\/eur-lex.europa.eu\/eli\/dec_impl\/2026\/2347\/oj\/eng\" rel=\"noopener\" target=\"_blank\">Implementing decision &#8211; EU &#8211; 2026\/2347 &#8211; EN &#8211; EUR-Lex<\/a> <span class=\"hsn-refs__url\">https:\/\/eur-lex.europa.eu\/eli\/dec_impl\/2026\/2347\/oj\/eng<\/span><\/li>\n<li id=\"hsn-ref-2\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-2\" aria-label=\"Back to reference 2 in the text\">\u21a9<\/a> <a href=\"https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/active_pharmaceutical_ingredients_leaflet_en_0.pdf\" rel=\"noopener\" target=\"_blank\">active_pharmaceutical_ingredients_leaflet_en_0.pdf<\/a> <span class=\"hsn-refs__url\">https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/active_pharmaceutical_ingredients_leaflet_en_0.pdf<\/span><\/li>\n<li id=\"hsn-ref-3\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-3\" aria-label=\"Back to reference 3 in the text\">\u21a9<\/a> <a href=\"https:\/\/health.ec.europa.eu\/medicinal-products\/falsified-medicines\/importation-active-substances-listing-third-countries_en\" rel=\"noopener\" target=\"_blank\">Importation of active substances &#8211; Listing of third countries &#8211; Public Health<\/a> <span class=\"hsn-refs__url\">https:\/\/health.ec.europa.eu\/medicinal-products\/falsified-medicines\/importation-active-substances-listing-third-countries_en<\/span><\/li>\n<li id=\"hsn-ref-4\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-4\" aria-label=\"Back to reference 4 in the text\">\u21a9<\/a> <a href=\"https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/qa_importation_0.pdf\" rel=\"noopener\" target=\"_blank\">health.ec.europa.eu \u2014 2016 11 \/ qa importation 0<\/a> <span class=\"hsn-refs__url\">https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/qa_importation_0.pdf<\/span><\/li>\n<li id=\"hsn-ref-5\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-5\" aria-label=\"Back to reference 5 in the text\">\u21a9<\/a> <a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32012D0715\" rel=\"noopener\" target=\"_blank\">L_2012325EN.01001501.xml<\/a> <span class=\"hsn-refs__url\">https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32012D0715<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>European Union drops the written confirmation for medicine ingredients made in Singapore, starting Nov. 15, 2026.<\/p>\n","protected":false},"author":1,"featured_media":2782,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_regnews_id":"35982","_hsn_citations":"[{\"n\":1,\"url\":\"https:\/\/eur-lex.europa.eu\/eli\/dec_impl\/2026\/2347\/oj\/eng\",\"label\":\"Implementing decision - EU - 2026\/2347 - EN - EUR-Lex\"},{\"n\":2,\"url\":\"https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/active_pharmaceutical_ingredients_leaflet_en_0.pdf\",\"label\":\"active_pharmaceutical_ingredients_leaflet_en_0.pdf\"},{\"n\":3,\"url\":\"https:\/\/health.ec.europa.eu\/medicinal-products\/falsified-medicines\/importation-active-substances-listing-third-countries_en\",\"label\":\"Importation of active substances - Listing of third countries - Public Health\"},{\"n\":4,\"url\":\"https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/qa_importation_0.pdf\",\"label\":\"health.ec.europa.eu \u2014 2016 11 \/ qa importation 0\"},{\"n\":5,\"url\":\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32012D0715\",\"label\":\"L_2012325EN.01001501.xml\"}]","_hsn_no_sources":"","_hsn_content_hash":"48bbf5819d12c09575439a4d1eb94e328d7b0f1c:75e9c3bd2e778b72522d3c0d36001a8a6542bf86","_yoast_wpseo_focuskw":"active pharmaceutical ingredients","footnotes":""},"categories":[150,7],"tags":[106],"class_list":["post-2783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe","category-pharma-medical","tag-european-union"],"_links":{"self":[{"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/posts\/2783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/comments?post=2783"}],"version-history":[{"count":1,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/posts\/2783\/revisions"}],"predecessor-version":[{"id":2784,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/posts\/2783\/revisions\/2784"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/media\/2782"}],"wp:attachment":[{"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/media?parent=2783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/categories?post=2783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hscodematch.com\/news\/wp-json\/wp\/v2\/tags?post=2783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}